Evaluating Trogocytosis as a Predictor for CAR-T Cell Therapy Success in Lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the role of trogocytosis, a process where immune cells acquire fragments of tumor cell membranes, as a potential predictive marker for the response to CAR-T cell therapy in patients with diffuse large B-cell lymphoma (DLBCL). By analyzing the level of trogocytosis in immune effector cells before and after CAR-T cell infusion, researchers aim to establish a correlation between these levels and patient outcomes at six months post-treatment. The study includes both patients undergoing CAR-T therapy and healthy volunteers for comparative analysis using flow cytometry techniques.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* For patients

  * Patient who has given free and informed consent in writing for inclusion in the non-interventional CART-BANK protocol, and orally for the CARTROG protocol,
  * Patients over 18 years of age at the time of inclusion,
  * Diagnosis of LDGCB,
  * Decision to treat with anti-CD19 CAR-T cells,
  * Patient affiliated to or benefiting from a social security scheme.
* For healthy volunteers:

  * Given free and informed oral consent for inclusion in the CARTROG protocol,
  * Donor between 18 and 70 years of age at the time of inclusion,
  * No history of solid cancer or hematological malignancy,
  * No known chronic pathology (e.g. hypertension, diabetes, etc.) and no daily treatment,
  * No surgical treatment within the last 6 months.

Exclusion Criteria:

* Patients who do not meet all the inclusion criteria,
* Pregnant or breast-feeding patient,
* Patient unable to follow the procedures and/or frequency of visits planned in the trial, for psychological, family, social or geographical reasons,
* Patient unable to consent freely to inclusion, under guardianship, curatorship or safeguard of justice.

Where it's running

• Clinical hematology department, University Hospital
  Montpellier, France Recruiting
• Clinical Investigation Center, University Hospital
  Montpellier, France Recruiting

Study contacts

• Principal investigator: Ludovic GABELLIER, MD — University Hospital, Montpellier
• Study coordinator: Valérie ROUILLE
• Email: v-rouille@chu-montpellier.fr
• Phone: +33467332645

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using itacitinib to improve CAR T cell therapy outcomes in lymphoma patients

  This study is testing if taking itacitinib before and after CAR T cell therapy can help improve outcomes for lymphoma patients with high inflammation levels.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT05757219

• In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

  This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07775508

• Anti‑PD1 armored CD19 CAR‑T therapy for relapsed or refractory diffuse large B‑cell lymphoma

  This trial will test whether anti‑PD1 armored CD19 CAR‑T cell therapy is safe and tolerable in adults with relapsed or refractory diffuse large B‑cell lymphoma.

  Recruiting Phase 1 Jiangsu Topcel-KH Pharmaceutical Co., Ltd. · Suzhou · NCT07368270

• CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma

  This trial tries CD5 CAR T-cell therapy, using either the patient's own cells or donor cells, and may bridge to stem-cell transplant for people 14–70 with relapsed or refractory T-cell lymphoma.

  Recruiting at 3 sites Phase 1/2 Beijing GoBroad Hospital · Beijing and 2 other locations · NCT07022964

• Glofitamab plus obinutuzumab for mantle cell lymphoma after CAR‑T

  This trial tests whether the antibody drug glofitamab given with obinutuzumab can shrink or control mantle cell lymphoma that returned or didn't respond after CD19 CAR‑T therapy in adults.

  Recruiting at 11 sites Phase 2 National Cancer Institute (NCI) · Duarte, California and 10 other locations · NCT07003295

• CD7 CAR T-Cell Therapy for T-Cell Lymphomas

  This study is testing a new CAR T-cell therapy for people with T-cell lymphomas that haven't responded to regular treatments to see if it is safe and effective.

  Recruiting at 4 sites Phase 1/2 Beijing GoBroad Hospital · Beijing, Beijing Municipality and 3 other locations · NCT06925464

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.